Figure 2. Granzyme C-expressing innate lymphocytes differentiate from ILCps, but not from NK cells, ILC2s, or ILC3s.

A. Experimental design for S1pr5 fate-mapper (S1pr5^FM) chimeric mice. Expression of S1pr5^FM and granzyme C (GzmC) in splenic (Spl), liver (Liv), and salivary gland (SG) CD3⁻NK1.1⁺ cells. B. Expression of S1pr5^FM in Liv and SG CXCR6⁺CD49a⁺, SG Eomes⁺CD49a⁺, and Liv CD49a⁻CD49b⁺ NK cells from S1pr5^FM chimeric mice. C. Experimental design for ILCp (Lin⁻CD127⁺α4β7⁺Flt3⁻CD25⁻PD-1⁺) transfer. Expression of CD49a and GzmC in Liv ILCp-derived CD3⁻NK1.1⁺NKp46⁺ cells. D. Experimental design for IL-5 fate-mapper (Il5^FM) mice. Expression of Il5^FM and GzmC in Liv, SG, and small intestine lamina propria (SI LP) Lin⁻Thy1.2⁺ and/or NK1.1⁺ innate lymphocytes. E. Experimental design for IL-17A fate-mapper (Il17a^FM) mice. Expression of Il17a^FM and GzmC in Liv, SG, and SI LP Lin⁻Thy1.2⁺ and/or NK1.1⁺ innate lymphocytes. F. Experimental design for IL-22 fate-mapper (Il22^FM) mice. Expression of Il22^FM and GzmC in Liv, SG, and SI LP Lin⁻Thy1.2⁺ and/or NK1.1⁺ innate lymphocytes. Each dot represents one mouse, n = 3–6 mice per group. All data are combined from three or more independent experiments and shown as mean +/− SEM (one-way ANOVA with Tukey’s multiple comparisons test, “ns” = not significant, * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001).